VIDEO: ASCO Plenary gives new data on adjuvant osimertinib

In this video, Julia K. Rotow, MD, medical oncologist at the Dana-Farber Cancer Institute, discusses presentations in lung cancer from the virtual ASCO annual meeting.

“I’m very happy to speak about some of the exciting advances we’ve seen for lung cancer at this year’s ASCO virtual annual meeting,” Rotow said.

Some of the data she found interesting included a plenary session about the adjuvant use of osimertinib (Tagrisso, AstraZeneca) and presentations about trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) for the treatment of HER2 non-small cell lung cancer.

“I always look forward to this presentation each year for these advances,” Rotow said. “This year was no exception.”

Reference:

Herbst RS, et al. Abstract LBA5. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Smit EF, et al. Abstract 9504. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview

Disclosures: Rotow reports serving in an advisory or consulting role for AstaZeneca, receiving travel, accommodations and expenses from Array and Eli Lilly, and receiving honoraria from Takeda.

Take Homes in Lung Cancer

Read more

VIDEO: ASCO Plenary gives new data on adjuvant osimertinib

Reference:

Related Content